Clinical trial EORTC-2139-MG - COLUMBUS-AD
Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group
| Cancers | |
|---|---|
| Organ | Skin |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | EORTC |
| EudraCT Identifier | 2021-004310-19 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05270044 |
| Last update |